Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort studyXue Bai, Zhong‐Yi Dong, Yi‐Long Wu et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 63
CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapyXue Bai, Zhong‐Yi Dong|Nature Communications|2023Cited by 58
PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung CancerLi-Li Long, Zhong‐Yi Dong|Cancer Research|2022Cited by 33
PAI-1-driven SFRP2high cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapyYan-Pei Zhang, Zhong‐Yi Dong, Ze-Qin Guo et al.|Cancer Cell|2025Cited by 30
Increased expression of OCT4 is associated with low differentiation and tumor recurrence in human hepatocellular carcinomaZhong‐Yi Dong, Li Liu, Qin Zeng et al.|Pathology - Research and Practice|2012Cited by 29